With more than twenty years of experience behind us, over time we have become a reference point in health and safety, and privileged interlocutors for hospitals, healthcare facilities and multinationals in this sector.
"It's not the tragedies that define our lives, but the choices we make to face them"Arrow up
In July 2018 Delta Med announced the acquisition of 77% of the capital of Bioengineering Laboratories Srl, strengthening its position in the vascular accesses market.
BEL is a company with a great international reputation, which deals with the development, production and distribution of certified and quality medical devices, in particular for vascular accesses for dialysis treatments and disposable devices for:
BEL is also involved in research and development activities, employing staff within the company and collaborating with other companies and research institutions: here is more information on the DIALYBRID project.
You may also be interested in: Delta Med acquires 77% of Bioengineering Laboratories
One of the major projects where the company is involved is DIALYBRID, regarding the development of an innovative, hybrid and semi-degradable, hemodialysis vascular access made of fibroin and polyurethane.
In this context, the company belonging to the Delta Med group:
1. registered the European trademark Silkothane®;
2. filed an international patent application regarding the Silkothane® vascular access ;
3. was awarded the prestigious “Seal of excellence” of the European Commission for its project DIALYBRID, submitted under the Horizon 2020’s “SME Instrument - Phase 1” call of May 3rd, 2018, and scored as a high-quality project proposal in a highly competitive evaluation process.
In addition to being selected for the European "SME Instrument - Phase 1" program, reserved for companies with high growth potential and market leader ambitions, BEL has already received a prestigious award for his DIALYBRID project.
In fact, at the 5th TERMIS (Tissue Engineering and Regenerative Medicine International Society) world congress, which took place in Kyoto from September 4 to 7, 2018, Bioengineering Laboratories received the second prize at the Business Plan Competition.
This is a competition that takes place in 3 rounds, which allows you to have the support of expert mentors to build, or improve, your business plan in the TERM sector: a showcase of great importance, given that, in addition to the prize provided for the winners, the finalists have the opportunity to present their project at the annual world congress, in front of professionals and experts.